Tactile Systems Technology, Inc. (TCMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Tactile Systems Technology, Inc. (TCMD) Healthcare & Pipeline Overview

Tactile Systems Technology, Inc. (TCMD) focuses on developing and marketing medical devices for chronic conditions like lymphedema and respiratory issues. Their product line, including Flexitouch Plus and AffloVest, offers non-invasive solutions for patients in the United States, positioning them in the competitive medical device landscape with a focus on at-home treatment.

What Is the Investment Thesis for TCMD?

Tactile Systems Technology, Inc. presents a compelling investment case within the medical device sector, driven by its focus on chronic disease management and innovative product offerings. With a market capitalization of $528M and a P/E ratio of 28.51, the company demonstrates profitability, supported by a gross margin of 75.7% and a profit margin of 5.9%. Key growth catalysts include the increasing prevalence of lymphedema and other chronic conditions, coupled with the growing demand for at-home treatment solutions. The company's focus on non-invasive therapies and its established distribution network in the United States provide a competitive advantage. Potential risks include regulatory hurdles, competition from established medical device manufacturers, and reimbursement challenges from healthcare payers. The company's beta of 0.99 suggests a moderate correlation with the overall market.

Based on FMP financials and quantitative analysis

TCMD Key Highlights

Market Cap of $528M indicates a mid-sized player in the medical device market.

• P/E ratio of 28.51 suggests investors are paying a premium for each dollar of earnings, reflecting growth expectations.
• Gross Margin of 75.7% demonstrates strong pricing power and efficient cost management.
• Profit Margin of 5.9% shows the percentage of revenue the company retains as profit after all expenses, indicating overall profitability.
• Beta of 0.99 suggests the stock's price is slightly less volatile than the overall market.

Who Are TCMD's Competitors?

TCMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TCMD's Key Strengths?

Innovative product portfolio targeting chronic diseases.

• Established distribution network in the United States.
• Strong gross margins indicating pricing power.
• Focus on non-invasive, at-home treatment solutions.

What Are TCMD's Weaknesses?

Limited geographic diversification.

• Reliance on reimbursement from healthcare payers.
• Competition from larger, more established medical device companies.
• Relatively small market capitalization.

What Could Drive TCMD Stock Higher?

Potential FDA approvals for new product lines or expanded indications for existing devices.

• Increasing prevalence of lymphedema and other chronic conditions driving demand for Tactile Systems Technology's devices.
• Strategic partnerships with healthcare providers and payers enhancing market access and reimbursement coverage.
• Continued investment in research and development leading to technological advancements and product innovation.

What Are the Key Risks for TCMD?

Insider selling — insiders were net sellers of roughly $1.2M recently.

• Regulatory changes and reimbursement pressures affecting the adoption of Tactile Systems Technology's devices.
• Competition from larger, more established medical device companies with greater resources.
• Economic downturn affecting healthcare spending and patient access to therapies.
• Product liability claims and recalls affecting the company's reputation and financial performance.

What Are the Growth Opportunities for TCMD?

• Growth opportunity 1: Expansion into new geographic markets represents a significant growth opportunity for Tactile Systems Technology. While the company currently focuses on the United States, there is potential to expand into international markets with similar demographics and healthcare needs. Timeline: 2-3 years to establish distribution networks and secure regulatory approvals in key international markets.
• Growth opportunity 2: Development of new product lines targeting related chronic conditions could drive revenue growth for Tactile Systems Technology. The company could leverage its expertise in pneumatic compression and high-frequency chest wall oscillation to develop devices for other conditions, such as peripheral artery disease or chronic obstructive pulmonary disease (COPD). The market for these devices is substantial, with millions of patients worldwide suffering from these conditions. Timeline: 3-5 years to develop and commercialize new product lines.
• Growth opportunity 3: Strategic partnerships with healthcare providers and payers can enhance Tactile Systems Technology's market access and reimbursement coverage. Collaborating with hospitals, clinics, and insurance companies can facilitate the adoption of the company's devices and ensure that patients have access to these therapies. This can involve bundled payment arrangements or value-based care models that incentivize the use of Tactile Systems Technology's devices. Timeline: Ongoing, as the company continues to build relationships with key stakeholders.
• Growth opportunity 4: Increased awareness and education among patients and healthcare professionals can drive demand for Tactile Systems Technology's devices. The company can invest in marketing and educational programs to highlight the benefits of its therapies and educate patients about the importance of early diagnosis and treatment of chronic conditions. This can involve online resources, patient support groups, and continuing medical education programs for healthcare providers. Timeline: Ongoing, as the company continues to invest in marketing and education.
• Growth opportunity 5: Technological advancements and innovation can enhance the performance and usability of Tactile Systems Technology's devices. The company can invest in research and development to improve the design, functionality, and connectivity of its devices. This can involve incorporating features such as remote monitoring, data analytics, and personalized therapy settings. These advancements can differentiate Tactile Systems Technology's devices from competitors and improve patient outcomes. Timeline: Ongoing, as the company continues to innovate and develop new technologies.

What Are TCMD's Competitive Advantages?

• Proprietary technology in pneumatic compression and high-frequency chest wall oscillation.
• Established distribution network in the United States.
• Strong relationships with healthcare providers and payers.
• Focus on non-invasive, at-home treatment solutions.

What Does TCMD Do?

Tactile Systems Technology, Inc., established in 1995 and headquartered in Minneapolis, Minnesota, is a medical technology company dedicated to creating and distributing medical devices designed for the treatment of chronic diseases. The company's core mission revolves around providing innovative, non-invasive solutions that improve the quality of life for patients suffering from conditions such as lymphedema, venous disorders, and respiratory ailments. Tactile Systems Technology's flagship product, the Flexitouch Plus system, is a pneumatic compression device specifically engineered for the treatment of lymphedema. This system utilizes gentle, sequential pressure to stimulate lymphatic drainage, reducing swelling and discomfort associated with the condition. The Entre system, another key offering, is a portable pneumatic compression device designed for at-home treatment of venous disorders, including lymphedema and chronic venous insufficiency, as well as venous leg ulcers. This device offers patients a convenient and effective way to manage their condition in the comfort of their own homes. Furthermore, Tactile Systems Technology offers AffloVest, a portable high-frequency chest wall oscillation device used in the treatment of retained pulmonary secretions. This device is particularly beneficial for patients with conditions like bronchiectasis, cystic fibrosis, and various neuromuscular disorders, helping them to clear their airways and improve respiratory function. Tactile Systems Technology distributes its products primarily within the United States, targeting healthcare providers and patients through a direct sales force and strategic partnerships.

What Products and Services Does TCMD Offer?

• Develops and provides medical devices for chronic diseases.
• Offers the Flexitouch Plus system for lymphedema treatment.
• Provides the Entre system for at-home treatment of venous disorders.
• Offers AffloVest for the treatment of retained pulmonary secretions.
• Focuses on non-invasive therapies for chronic conditions.
• Distributes products primarily in the United States.

How Does TCMD Make Money?

• Develops and manufactures medical devices for chronic diseases.
• Sells devices directly to healthcare providers and patients.
• Generates revenue through product sales and rentals.
• Focuses on reimbursement from healthcare payers.

What Industry Does TCMD Operate In?

Tactile Systems Technology operates within the medical device industry, which is characterized by continuous innovation, stringent regulatory requirements, and evolving reimbursement policies. The market for medical devices targeting chronic diseases is expanding, driven by an aging population and increasing prevalence of conditions like lymphedema and respiratory disorders. Competition is intense, with established players and emerging companies vying for market share. Tactile Systems Technology differentiates itself through its focus on non-invasive, at-home treatment solutions, aligning with the trend towards patient-centric care and cost-effective healthcare delivery.

Who Are TCMD's Key Customers?

• Patients with lymphedema.
• Patients with venous disorders.
• Patients with respiratory ailments.
• Hospitals and clinics.
• Healthcare providers.

Company Profile

Tactile Systems Technology, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO Sheri Louise Dodd. TCMD has traded publicly since 2016.

Return on equity for Tactile Systems Technology, Inc. stands at 11.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.9%, showing how much profit it generates from its asset base. TCMD trades at a trailing price-to-earnings ratio of 22.07, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.5%, the inverse of the P/E and a quick read on earnings relative to price.

TCMD Valuation & Market Position

With a $528M market cap, Tactile Systems Technology, Inc. sits in the small-cap segment of the market. Relative to its peer group, TCMD's quantitative score of 91/100 is above the peer average of 74/100.

Quarterly Financial Performance: Tactile Systems Technology, Inc.

Revenue for Tactile Systems Technology, Inc. came in at $85.7M during Q2 2026, a 13.9% improvement versus the preceding quarter. The company recorded net income of $7.8M, with diluted EPS of $0.34. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, TCMD averaged $0.27 in diluted EPS.

Tactile Systems Technology, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.19 places it in the safe zone, indicating low near-term bankruptcy risk.

Tactile Systems Technology, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 35.3% above estimates on average.

Wall Street analysts project Tactile Systems Technology, Inc. revenue of about $362.0M for fiscal 2026, with EPS near $1.09. The estimate reflects 4 contributing analysts.

Over the past six months, Tactile Systems Technology, Inc. insiders filed 14 SEC Form 4 transactions — 5 sales and 9 purchases. On net that is roughly 12K shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.

TCMD Financials

TCMD Latest News

TCMD Analyst Consensus

TCMD MoonshotScore

Latest Tactile Systems Technology, Inc. Analysis

Common Questions About TCMD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources